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Background
Ketamine has recently received considerable attention regarding
its antidepressant and anti-suicidal effects. Trials have generally
focused on short-term effects of single intravenous infusions.
Research on patient experiences is lacking.
Aims
To investigate the experiences over time of individuals receiving
ketamine treatment in a routine clinic, including impacts on
mood and suicidality.
Method
Twelve fee-paying patients with treatment-resistant depression
(6 females, 6 males, age 21–70 years; 11 reporting suicidality and
6 reporting self-harm) who were assessed as eligible for keta-
mine treatment participated in up to three semi-structured
interviews: before treatment started, a few weeks into treatment
and ≥2 months later. Data were analysed thematically.
Results
Most participants hoped that ketamine would provide respite
from their depression. Nearly all experienced improvement in
mood following initial treatments, ranging from negligible to
dramatic, and eight reported a reduction in suicidality.
Improvements were transitory for most participants, although
two experienced sustained consistent benefit and two had sus-
tained but limited improvement. Some participants described
hopelessness when treatment stopped working, paralleled by
increased suicidal ideation for three participants. The transient
nature and cost of treatment were problematic. Eleven partici-
pants experienced side-effects, which were significant for two
participants. Suggestions for improving treatment included clo-
ser monitoring and adjunctive psychological therapy.
Conclusions
Ketamine treatment was generally experienced as effective in
improvingmood and reducing suicidal ideation in the short term,
but the lack of longer-term benefit was challenging for partici-
pants, as was treatment cost. Informed consent procedures
should refer to the possibilities of relapse and associated
increased hopelessness and suicidality.
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Ketamine for treatment of depression
The use of ketamine in the treatment of depression has attracted
much attention, with some viewing it as the first ‘breakthrough’
new treatment for affective disorders in the past few decades.1
Ketamine has primarily been used therapeutically in psychiatry
for people experiencing depression that has proved difficult to
treat, commonly referred to as treatment-resistant depression
(TRD).2,3 Reviews of single intravenous doses of ketamine in uni-
polar depression indicate that it can reduce depressive symptoms
compared with either inert or active placebo, but the effects are
transitory.4,5
Individuals with TRD often experience suicidal thinking and
have increased risk of suicidal acts.6 The use of ketamine to try and
reduce these phenomena has also received recent attention.7–9
Reviews of trials have demonstrated that a single intravenous treat-
ment with ketamine can have beneficial effects on suicidal ideation,
but again with transitory benefits,10,11 possibly of shorter duration
than the effects on depression. There is no evidence regarding
actual suicidal acts.10
Most earlier trials of ketamine treatment for depression or sui-
cidal ideation in the context of TRD involved single infusions.4,5,10
Because of the often temporary benefits of a single dose of ketamine,
in clinical practice multiple doses may be given and patients might
be transferred to othermodes of ketamine treatment (e.g. oral, intra-
muscular) once they have shown improvement with intravenous
treatment.12 Research into repeated treatments has been increasing.
For example, Murrough et al studied longer-term outcomes of 24
individuals following a course of six infusions over 2 weeks, and
found variability in duration of positive response from 4 to 83
days.13 Phillips et al found that patients with a positive response
in mood ratings to a single ketamine infusion, which was
maximal at 7 days post-infusion, subsequently had sustained reduc-
tion in suicidal ideation with repeated weekly infusions.14 Review of
clinical case records has indicated benefits of repeated ketamine
infusions in a sizeable proportion of patients.15 However, there is
a shortage of qualitative studies of patients’ experiences over time.
Thus, little is known about patients’ views of ketamine treatment
for depression, including their expectations, concerns and general
thoughts about the impact of treatment in both the short and
longer term. This is particularly important given that some
authors have urged caution regarding provision of ketamine treat-
ment getting ahead of evidence of effectiveness.16,17 Concerns
have also been expressed about the impact on patients where the
treatment fails, an initial impact reverses or when patients have to
cease therapy because of insufficient funds to cover the cost.18
The current study
The aim of this study was to explore the experiences and perspec-
tives of patients with TRD who received ketamine treatment. We
wanted to investigate their expectations of ketamine, short- and
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longer-term effects of treatment on mood and suicidal ideation,
experiences of side-effects and overall views on ketamine treatment.
This research was carried out as part of a wider qualitative
inquiry, which also involved investigating the impact of ketamine
treatment on suicidal ideation.19
Method
The study participants were self-funding patients attending a single
ketamine clinic in the UK. Inclusion criteria were aged 18 years or
over, having TRD, assessed to be an appropriate candidate for keta-
mine treatment and agreeable to treatment, no previous ketamine
treatment for depression, capacity to consent and fluency in the
English language. The criteria used by the clinic for suitability for
treatment with ketamine were as follows: currently suffering from
depression, have tried at least two different types of antidepressants
for at least 6 weeks each at an adequate treatment dose, and have
tried at least one type of psychological treatment.
Standard practice at this ketamine clinic is three intravenous
ketamine infusions (0.5 mg/kg), each 1 week apart, followed by a
break of 3–4 weeks, after which a clinical review takes place. At
this review it is established whether patients have responded posi-
tively to treatment, i.e. treatment has resulted in a reduction of
depressive symptoms to the degree that ongoing treatment is
viable. At the time of recruitment into this study, further individua-
lised treatment could take the form of regular oral ketamine (first
administered at the clinic and subsequently taken at home, generally
twice a week, with variable doses according to each individual’s
response), a combination of regular oral and intermittent intraven-
ous ketamine, or intermittent intravenous ketamine only. No add-
itional treatments are prescribed at the ketamine clinic, although
patients typically remained on other oral antidepressants.
Recruitment
Individuals newly referred to the ketamine clinic who were assessed
to be appropriate for ketamine treatment during the recruitment
phase of the project were invited to take part in the study and
given participant information sheets by ketamine clinic clinicians
(R.M., H.T.). Interested individuals were referred to the researcher
(K.L.), who provided more information and carried out the
informed consent process. Written informed consent was obtained
from all participants.
Of 38 patients initially approached by the clinic staff, 12 (31.6%)
agreed to participate in the study.
Data collection
The interviews took place between May and December 2017.
Participants were invited to be interviewed on three separate occa-
sions: before treatment started, around 2 weeks after initiation of
treatment and after approximately 2 months of treatment (or fol-
lowing completion of treatment if participants stopped receiving
ketamine within 2months). Because of the limitations of participant
availability, the timings between interviews varied somewhat.
Participants were also invited to keep a diary to record their treat-
ment experiences, either in paper diary form or via the ‘notes’
section of a daily mood-monitoring platform, through which the
Quick Inventory of Depressive Symptomatology (Self-Rated)20
was routinely completed (‘True Colours’).
One-to-one semi-structured interviews were carried out by the
researcher (K.L.). Eleven out of twelve of the first interviews were
face to face at the hospital site where the ketamine clinic is based,
as were subsequent interviews for seven participants. The remaining
interviews were via phone, Skype or Facetime.
Before each interview participants completed the Beck
Depression Inventory (BDI),21 a widely used, 21-item self-rating
scale to measure severity of depression, with each item having
four possible responses scored between 0 and 3.
The first interview focused on participants’ clinical history,
how they found out about ketamine treatment and their hopes,
expectations and anxieties about treatment. Subsequent interviews
addressed participants’ experiences of treatment, including
impacts on mood and suicidal ideation, and side-effects of treat-
ment. At the third interview participants were asked about their
overall perspectives on the treatment. A copy of the interview sche-
dules is provided in the Supplementary Appendix 1 available at
https://doi.org/10.1192/bjo.2020.132.
The interviews lasted for 20–60 min and were tape-recorded for
later verbatim transcribing (by K.L. and F.B.). Participants were
given the opportunity to receive copies of their transcripts and, 18
months following their final interview, were invited to provide a
retrospective paragraph via email with any additional reflections
on treatment. Two participants requested their interview transcript
and retrospective paragraphs were received from two further parti-
cipants. Paper diaries were completed by three participants, and one
participant kept regular notes on the electronic self-monitoring
system used by the ketamine clinic (True Colours). Because of the
limited response to diary-keeping and email, the results of this
study are predominantly based on the interview data.
Data analysis
The interviews were transcribed and thematic analysis carried out to
identify participants’ experiences and their explanations for these,
using an inductive semantic approach, following the stages of ana-
lysis recommended by Braun and Clarke.22 Themes were first iden-
tified in relation to individuals over the course of their interviews
and then across the whole sample, using the principle of ‘following
the thread’23 to bring the different data components together. Final
agreement on themes was based on consensus discussion between
two researchers (K.L. and F.B.), with supervision from L.M. The
analysis was supported by NVIVO software (QSR International
(2008) NVivo Qualitative Data Analysis Software (version 11); see
http://www.qsrinternational.com).
Patient and public involvement
A former patient of the ketamine clinic provided feedback on the
interview schedule and participant information materials before
submission for ethical approval.
Ethical approval
The authors assert that all procedures contributing to this work
comply with the ethical standards of the relevant national and insti-
tutional committees on human experimentation and with the
Helsinki Declaration of 1975, as revised in 2008. All procedures
involving human subjects/patients were approved by the South
Central Oxford Research Ethics Committee and the Health
Research Authority (reference number 17/SC/0106). The completed
Consolidated Criteria for Reporting Qualitative Research Checklist
can be accessed in Supplementary Appendix 2 available at https://
doi.org/10.1192/bjo.2020.132.
Results
The study sample comprised 12 individuals (6 females and 6males),
with a median age of 57 years (range 21–70 years). Participants had
suffered with depression for between 10 and 50 years and two
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participants had additional diagnoses (bipolar disorder type 1 and
obsessive–compulsive disorder). All had tried several pharmaco-
logical and psychological treatments, and three participants
had received electroconvulsive therapy. Eight individuals were
taking antidepressant medication at the time of recruitment into
the study, with four participants taking two or more different
types. Of these, two participants were also taking mood stabilisers
and two participants were taking anxiolytics (one participant was
taking all three types of medication). Antidepressant medication
included a range of selective serotonin reuptake inhibitors, a sero-
tonin–noradrenaline reuptake inhibitor (venlafaxine), mirtazapine,
quetiapine and bupropion. Four participants were currently
engaged in psychological treatments, namely counselling/therapy
(n = 2), cognitive–behavioural therapy (n = 1) and psychosocial
intervention (n = 1).
Suicidal ideation had been experienced at some point by all par-
ticipants, to varying degrees of frequency and intensity, from a
single fleeting thought without intent to strong ideation with
reported intent and suicidal acts. Six participants had a history of
self-harm. Key participant characteristics are presented in Table 1.
Eight participants attended all three research interviews. Three
participants attended only the first two interviews as treatment was
terminated after a single dose because of side-effects (n = 1), or self-
withdrew from treatment after two infusions because of nil or
limited effect (n = 2). A fourth attended the first and third interviews,
but had been uncontactable at the time the second interview was due.
The time points at which interviews took place varied because of
availability for interview or delayed response to contact. Seven of the
eleven second interviews took place at the planned time period of 2
weeks into treatment, and the remaining four took place between 1
week and2months after the first interview. Eight of thenine third inter-
views were carried out between 5 and 12 weeks after the second inter-
view and, in the case of the participantwhoattended interviews one and
three only, the third interview took place 4 months after the first.
Ten participants had at least three intravenous ketamine treat-
ments, with six going on to oral treatment. Six participants were still
engaged in ketamine treatment by the end of the study period. A
summary of treatments received is provided in Table 2.
Self-reported findings from the interviews are summarised and
presented below, in both numeric and narrative format, covering
pre-treatment experiences and expectations, short- and longer-
term impact of ketamine on mood and suicidal ideation, side-
effects of treatment and participants’ perspectives on ketamine
treatment overall.
Pre-treatment: finding out about ketamine treatment
and expectations of it
Most participants found out about ketamine treatment by internet
searching for treatments for depression (n = 5) or through national
news coverage (n = 4). Two participants were informed about the
treatment by their psychiatrist and one participant noticed an
improvement in mood following recreational ketamine use, which
prompted internet searching for therapeutic treatment.
All participants described some sense of anticipatory hope that
the ketamine treatment would stimulate changes in their mood and
functioning:
‘Hopefully it might just give me the kick start to be able to get
me off some medication so that I can start building up my life
again.’ (P1, interview 1)
Half of the participants (n = 6) moderated their anticipatory hope
based on past experiences of treatments not working. When asked
to contemplate how they might feel if the treatment did not work,
five participants said they would be disappointed but at the same
time would be pleased they had tried it, four were unsure and
three implied that they would feel a sense of hopelessness:
‘I don’t know really. Don’t know where to go from there really.
Don’t know what else there is. I’m just hoping it does (work).
I get the impression there isn’t anything else really then. I’ve
tried most things.’ (P4, interview 1)
The main concerns about treatment were to do with it not working
(n = 5) and side-effects, particularly the dissociative and psychoto-
mimetic effects (n = 6). Two participants stated that they had no
concerns at all. No participants expressed anxieties about possible
development of dependency on ketamine.
Impact of treatment on mood and suicidal ideation
Ten participants reported experiencing a positive impact on mood
at some point during their course of ketamine treatment, including
one who had a single infusion only before being withdrawn from
treatment because of side-effects. The remaining two individuals
were classed as non-responders, i.e. benefit was not enough to indi-
cate that treatment was effective. Intensity and duration of improve-
ments varied considerably from treatment to treatment and person
to person, lasting from a few hours after treatments to some weeks.
Symptomatic benefits associated with improved mood were most
commonly reduced anxiety (n = 10), improved sense of self-worth
(n = 9) and increased energy (n = 8). Three participants reported
an improvement in appetite, and in three other participants this
manifested as more moderated eating because of reduced urges to
overeat.
Table 1 Participant characteristics
Characteristics N = 12
Gender (male/female) 6/6
Age, years 21–70; median 57
Beck Depression Inventory scores Range 22–49; mean
32.9 (s.d. 8.5)
Past suicidal ideation 12
Suicidal ideation reported at interview 1 (Beck
Depression Inventory question 9)
11
Past self-harm 6
Table 2 Summary of treatments received (N = 12)
Mode of treatment (n) Explanation for cessation or maintenance of treatment
One infusion only (n = 1) Stopped because of side-effects but experienced some transient benefit
Two infusions only (n = 1) Limited improvement not considered enough to justify expense and travel
Three infusions only (n = 2) One non-responder; one responder with significant and sustained improvement
Four infusions only (n = 2) One non-responder; one responder still engaged in intravenous treatment at end of study with significant
but transitory improvement, somewhat diminished by study end
Two infusions and oral for approximately 11
weeks (n = 1)
Ceased treatment because of limited and diminished improvement
Infusion and oral and still engaged in treatment by
end of study (n = 5)
One significant and sustained improvement; two ongoing improvement still present but somewhat
diminished by end of study; two significant but transitory benefit, no longer present by study end
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The main themes relating to the lifestyle outcomes of improved
mood were improved functionality (n = 9), becoming less self-
critical (n = 9) and being able to socialise (n = 9):
‘I think the best thing is the lack of mental pain but what feels
best is [physically] clearing a room……. That’s kind of what
gives me the (big sigh) feeling.’ (P3, interview 3)
‘I played golf yesterday and I didn’t play very well but I didn’t
feel anxious, then we went to the pub afterwards ……. and
yeah, I felt really quite relaxed if you like … I wasn’t sitting
there worrying about myself and worrying about what other
people think of me …..’ (P4, interview 2)
Initial impact (first two treatments)
Nine participants noticed some improvement in mood after the first
ketamine treatment: two during the infusion, four the following day
and three a few days later. These improvements lasted between a day
and right through to the next treatment (1 week). Generally, early
effects on mood were mild (n = 6), although three participants
described more significant benefits such as the feeling of being
back to their old self (n = 1), feeling on form (n = 1) and a reduction
in psychosomatic gastrointestinal symptoms (n = 1).
The second ketamine infusion stood out for five participants as
being significantly more effective than the first, with four partici-
pants describing striking changes that were life-changing while
they lasted and not experienced to the same degree following subse-
quent treatments:
‘I felt alive. I wasn’t watching my life going past me anymore, I
was part of it.’ (P2, interview 2)
‘I’d almost say it cured, it’s cured, if you like, my depression….
cure, or relief from.’ (P5, interview 2)
Eight participants reported a reduction in suicidal ideation.
Participants tended to associate this with improved mood. Some
were starkly aware that they no longer had suicidal ideas (n = 4),
whereas for others there was a more subtle realisation that they
had not been having such ideas, or they were less intense (n = 4).
Again, the second ketamine infusion resulted in the most profound
reduction in suicidal thoughts:
‘It was like a weight had been lifted, it really was. It was quite
amazing really. I could do things again; I could go out……I
wasn’t thinking about suicide…’ (P4, interview 2)
‘In the past [2 days] I don’t think that’s come into my head in
anyway whatsoever. It’s like, huh, why would I do that? Was I
thinking about that before? Yes, I have, I’ve been very suicidal,
now that place in my brain isn’t active.’ (P3, interview 2)
Where positive effects on mood were experienced following the
second treatment, these generally lasted until the next treatment,
with some participants noticing a tapering of effect. This resulted
in a return of suicidal ideation in some, but not all participants.
Subsequent impact (third treatment onward)
Ten participants had three or more ketamine treatments. Of these,
two reported sustained improvements, two were non-responders
and six reported that the positive effects of ketamine waned some-
what over time. In three of these six participants, suicidal ideation
remained absent or reduced despite periods where improvements
in mood were not sustained, but the other three participants
described a return of strong suicidal thoughts as the positive
effects on mood wore off. These thoughts involved consideration
of suicide methods and, in two participants, some ambivalent pre-
paratory behaviour.
Six participants progressed to oral ketamine treatment, with
four noting it to be less effective than the infusions. For some, this
resulted in a sense of hopelessness, whereas others maintained
hope that the ketamine treatment might work again:
‘I suppose when I went to the oral after the change in the doses
2–3 times I started to lose a bit of confidence or hope in the
treatment as such, that saddened me because I did think at
the time I might really have a way forward but unfortunately
those feelings have now diminished [……….] Initially [the
doctor] described my situation as heading towards oblivion
and, to be honest I feel that I’m probably going down that
step again.’ (P5, interview 3)
‘It all went downhill……quite far. I can’t remember whether I
was actually suicidal at all, possibly not but I was very anxious
for something to be fixed, to be helped…… I’m still holding
onto the hope that maybe we can improve……. I’m now
feeling that maybe with regular oral doses it might improve a
little bit, so I’m holding onto that hope.’ (P3, interview 3)
Two individuals found oral ketamine to be more beneficial than the
intravenous infusions. This was explained as possibly being a result
of the cumulative effect for one participant, and because the dis-
sociative treatment effects were less intense than with the infusions
for the other participant.
Half of the participants (n = 6) were still in treatment at the end
of the study. One of these participants described a sustained and sig-
nificant improvement in mood, which had resulted in holistic posi-
tive effects:
‘I can function like I used to before I got depressed. It’s given
me my life back.’ (P1, interview 3)
Three of the remaining five participants reported ongoing but dwin-
dling positive effects on mood, and two indicated that noticeable
improvements had ceased. As with previous interviews, for some
the fact that ketamine had worked for a time instilled hope for
the future:
‘At themoment it’s bad again…… there is hope now, so before
there wasn’t…….what I know now is that there is a chance to
get better.’ (P2, interview 3)
Of the six participants who had stopped ketamine by the end of the
study, one had sustained improvement in mood with a single course
of three ketamine infusions and the remaining five had stopped
because of non-response (n = 2), insufficient efficacy (n = 2) or
side-effects (n = 1). One of these described feeling worse as a
result of the ketamine treatment not working, and reported a
sense of associated hopelessness:
‘So generally I think I feel worse…. I feel more hopeless……
Maybe I built up too much hope for it because I tried lots of
other things beforehand and it seemed like this was going to
be, kind of a salvation. I guess that as its not, that’s probably
contributed to my mood. I feel pretty kind of, oh shite, what
do I do now, you know?’ (P6, interview 2)
Responses to treatment are summarised in brief in Table 2. Changes
in BDI scores over the period of the study reflected participants’
narratives. These scores are shown graphically and statistically in
Supplementary Appendix 2 available at https://doi.org/10.1192/
bjo.2020.132.
Side-effects of ketamine treatment
Side-effects during treatment administration were prominent, par-
ticularly dissociation, which was experienced by 11 out of 12 parti-
cipants. Other effects noted were seeing or hearing unusual things
(n = 6), blurred vision (n = 5) and nausea (n = 3). For most
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participants (n = 10) these effects lasted less than an hour or
between 1 and 3 hours.
Experiences of the first intravenous ketamine treatment ranged
from pleasant (n = 3) to unpleasant (n = 2), with most (n = 7) some-
where in between. Descriptions related mainly to dissociative and
psychotomimetic effects of the treatment and wooziness or fuzzy
headedness, although there was also some reference to feeling
heavy (n = 4):
‘I felt like I was in a spaceship looking out down on the
world….I felt relaxed….it was quite a pleasant experience….
it was almost out of body in terms of you’re almost looking
at yourself as a spectator rather than actually being part.’
(P5, interview 2)
‘It was horrible. I felt very drunk and very heavy and I must
have taken quite a long time, to come round…….and I think
I was pretty washed out at the end of it. It was not a pleasant
experience at all.’ (P9, interview 2)
Eleven participants experienced side-effects following ketamine
treatment, which were reported as significant in two participants
and minimal or minor in the remaining nine participants.
Tiredness for a day or so after intravenous treatments was
common (n = 6), as were headaches (n = 4), which for three partici-
pants were minor and continued for up to a day after treatment,
although one individual experienced a debilitating 4-day long head-
ache, which commenced 2 days after the first ketamine infusion.
This was classed as a severe side-effect resulting in termination of
treatment. Less common side-effects were gastrointestinal symp-
toms with oral ketamine (n = 1), and sustained sleep disturbance
(n = 1).
Most participants did not have any concerns about ketamine
tolerance or dependency, although three reflected that a sense of
addiction might be a possibility:
‘I don’t mind taking it because I know it’s not a horrible sensa-
tion that you’re getting. So I suppose in that sense you’ve got a
slight addiction in the sense that you don’t mind taking it.’ (P1,
interview 3)
‘I think if it did work I probably could get addicted to it to be
honest but based on them two infusions, never.’ (P11, inter-
view 2)
One participant had some concerns about misuse of ketamine if
they resorted to accessing street ketamine to avoid the cost of
ongoing therapeutic ketamine treatment.
Overall perspectives on treatment
At the last point of contact in the study, significant and ongoing
improvement in mood was reported by two study participants,
and a further three reported more limited residual benefits. For
five other individuals, improvements had ceased and the remain-
ing two individuals did not derive any benefit from ketamine
treatment.
Ketamine treatment met or exceeded expectations for five par-
ticipants. This included three participants for whom improvement
had plateaued or diminished. Three individuals were clear that
their expectations had not been attained. Others said they had not
held any expectations (n = 2) or that they had beenmet in part (n = 2).
The expense of treatment was problematic for some participants
(n = 5), especially when they were not deriving ongoing benefit:
‘I feel quite dispirited really. Because it’s been really expensive.
You know, I haven’t been anywhere or done anything because
all my money has gone on this, so I don’t feel great about it at
the moment.’ (P7, interview 3)
The short-lived effect of treatment was frustrating for participants
who experienced transient benefit, from a cost perspective and
from resulting difficult emotions and fluctuating levels of hope:
‘My treatments with ketamine were wholly beneficial for
myself and greatly improved my mood although only for a
relatively short time. If the cost of the treatment was
reduced, I would like to have had more treatments but at the
present time I lack the necessary funds.’ (P4, email
correspondence)
‘I was a bit angry and sad…….. I couldn’t believe it [improved
mood] stopped and [I was] just back the way I was. It’s sad
because, I hope if in the future I’m going to do this again, I
kind of want to do it and hopefully this is going to get better
with longer treatment, but if it doesn’t it, you know, it makes
me think that, what’s the point of living.’ (P2, interview 3)
Participants who did not derive lasting benefit from ketamine were
nevertheless generally positive about the availability of an alterna-
tive to traditional antidepressants. Some volunteered helpful sugges-
tions for improving treatment experiences, such as more
individualised dosages (n = 2); closer monitoring by clinic staff via
phone calls or email (n = 3); candid discussion of the need to
manage expectations, including patients being made aware of that
there were no guarantees of benefits, the risk of relapse and possible
short duration of effects (n = 2); and to balance the financial impli-
cations with an uncertain outcome (n = 3). One participant was
keen that adjunctive psychological therapy should be offered along-
side ketamine treatment, and others reported being able to make
better use of existing psychological therapy (n = 2) or openness to
engaging in therapy (n = 2).
Discussion
In this qualitative study we investigated the experiences and per-
spectives of patients undergoing ketamine treatment for TRD. As
far as we are aware, this study is the first to examine patient
experiences over time. Most participants involved in this research
derived some benefit from ketamine, but there was considerable
variability in terms of intensity and duration, ranging from negli-
gible and/or short term to substantial and sustained improve-
ment. The main benefits described were improved mood and
reduced suicidal ideation, with associated positive outcomes of
improved functionality and socialisation and reduced anxiety
and self-critical thoughts. However, loss of effectiveness over
time and consequent declines in hope were marked in some.
For those who derived benefit, improvements were maintained
in two participants, diminished to varying degrees over time in
six participants and waned quickly and completely in two
participants.
Our findings reflect those from case report studies of a similar
number of individuals with TRD who were tried on maintenance
ketamine therapy,24,25 which also showed that most patients experi-
enced initial but not ongoing improvement.
Impact on mood
Noticeable improvements in mood occurred at varying time points
and for differing lengths of time, ranging from days to weeks. This
reflects what is known from trials that suggest improvement in
mood usually lasts for between 1 and 2 weeks, longer in a minority
of cases.4,5,8 In our research the second intravenous ketamine treat-
ment resulted in marked improvement for some participants, which
lasted longer than benefits following the other ketamine treatments.
Some patients went on to oral treatment with ketamine following
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the initial intravenous treatment, but with mixed responses. It is
recognised that bioavailability of ketamine delivered by the oral
route is relatively lower.26
Impact on suicidal ideation
Most participants who reported a reduction in suicidal ideation
associated it with improvement in mood. For some, however, sui-
cidal thoughts remained alleviated even when their mood began
to deteriorate. This indicates a possible independent effect, which
has been tentatively identified in recent reviews of the impact of
ketamine on suicidal ideation10,11 and in a previous qualitative
study.19
Side-effects and other consequences of ketamine
treatment
Reflecting wider research into the effects of ketamine treat-
ment,13,27,28 participants in this study perceived the main side-
effects of ketamine treatment to be those experienced during intra-
venous treatment administration, particularly dissociation and
strange or unreal sensations, which were transient and resolved
shortly after treatment. Side-effects following treatment were
mainly fatigue and headaches, which are again commonly reported
in the literature.28
A minority of our participants thought that there might be a
possibility of dependency on ketamine occurring over time.
Dependency has not been identified as an adverse outcome of keta-
mine treatment,27 although concerns about misuse potential have
been raised,18,29-31 including risk of illegal procurement. One indi-
vidual in our study referred to a possibility of purchasing street keta-
mine to self-medicate because it was cheaper and more locally
accessible than therapeutic ketamine treatment. This view has also
been expressed by actual or potential ketamine patients in other
studies.18,32 The possibility of this occurring cannot be ruled out
for some patients, particularly given the widespread availability
and low cost of recreational ketamine.
Most participants in our study found out about ketamine via the
media, suggesting that widespread reporting attracts individuals
who are searching for novel treatments to provide respite from
depression. A sense of desperation for effective treatment has
been reported by prospective ketamine patients,32 and concerns
have been expressed that such desperation might lead individuals
to home in on the reported benefits of ketamine and overlook the
limitations, leading to dashed hopes.31 Similar experiences have
been reported for other treatments that are sometimes used in
severe mood disorders, such as deep brain stimulation, where
media hype and the challenges of trying to modify unrealistic expec-
tations are common features.33,34 Hope was a large part of the keta-
mine treatment experience: hope that it might work, hope when it
did work, hopelessness (in some cases) when it stopped working
and hope that it might work again. For some participants, hopeless-
ness was related to the impossibility of long-term treatment because
of lack of funds, which suggests that these feelings might be related
both to beneficial effects of ketamine wearing off and concerns
about availability of alternative treatments. Similar cases are
described elsewhere,17,35 which have contributed to suggestions
that adjunctive psychosocial interventions17 and closer monitoring
of ketamine patients35 may augment beneficial outcomes and
ensure early identification of relapse. These suggestions have also
been made by patients.18 Some individuals in our study identified
a need for closer monitoring and, with regard to psychological
input, one participant thought that it should be provided soon
after treatment-related dissociative and psychotomimetic effects
have worn off because, in their experience, receptiveness will be
optimised at this point because of improved mood and openness
to the possibility of change.
Strengths and limitations
A strength of this study is that it was conducted in a routine clinic
setting rather than a trial, so there were no formal inclusion/exclu-
sion criteria beyond that participants had TRD and were treated
with ketamine. Although the results of this study are not necessarily
generalisable, the qualitative approach adopted is advantageous in
that it provides a nuanced understanding of experiences of patients
and thus a more complete overview of the effects of ketamine treat-
ment than clinical trials alone. Given the heterogeneity of patients
with TRD, clinical trials that adopt pragmatic inclusion criteria
may attract a wider diversity of patients, including those without
financial means to pay for treatment. We suggest that such trials
should incorporate nested qualitative studies to enable patient
experience to be included to provide more complete study
outcomes.
The small number of participants in this study is a limitation,
as is the relatively short duration of follow up. Also, because of
participant availability, there was some inconsistency in the
time periods between interviews and the number of interviews
attended, which, along with the variations in treatment courses
based on the individualised approach of the clinic, may have
added to the variability of responses. However, these factors
represent normal aspects of routine provision of treatment with
ketamine. Self-report from the semi-structured interviews rather
than validated clinical scales was largely relied upon when
seeking information about changes/improvements to mood and
hopelessness, to gain a full understanding of patients’ experiences.
However, the BDI was used to obtain a more objective measure of
mood at key points throughout the study. All participants had the
financial means to fund treatment, which does not reflect the
wider TRD population, most of whom would not be able to
afford self-funded treatment.
Recently, delivery of ketamine in the form of esketamine, the S-
enantiomer of ketamine, via a nasal spray has been developed, with
some promising results when combined with an antidepressant.36
Although the USA Food and Drug Administration has approved
the use of esketamine in combination with an antidepressant for
TRD37 and the European Commission has given similar approval,38
the UK National Institute for Health Care Excellence has not
approved its use in the National Health Service.39 We do not
know if the findings of this study would be reflected in patients
receiving esketamine nasal spray treatment according to the
licensed doses.
In conclusion, the findings from this qualitative study of patient
experiences when receiving treatment with ketamine complement
those from treatment trials. They indicate some benefits for mood
and suicidal ideation in the majority of patients, but with reductions
in these benefits over time for most, but not all, initial responders to
treatment. They also suggest that there should be caution regarding
overly optimistic interpretation of the place of ketamine treatment
in the management of TRD. Informed consent procedures should
include reference to the high likelihood of relapse. Together with
the current cost of treatment, especially for individuals who cease
to be able to afford it, this has the potential to increase hopelessness.
There is also a major need to investigate whether adjunctive therap-
ies, especially psychological ones, can help sustain early benefits of
treatment.
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